Mode
Text Size
Log in / Sign up
Phase 3 N=50 Treatment

Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Body Mass Index (BMI) Between 30-40 kg/m2

Obesity

Enrolled (actual)
50
Serious AEs
28.0%
Results posted
Mar 2015
Primary outcome: Primary: To Determine Percent of Excess Weight Loss (%EWL) After Laparoscopic Adjustable Gastric Banding Surgery — 51.74 percentage of excess weight loss

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
LAP-BAND® Adjustable Gastric Band (LAGB®) (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
NYU Langone Health
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
To Determine Percent of Excess Weight Loss (%EWL) After Laparoscopic Adjustable Gastric Banding Surgery
51.74
SECONDARY
Level of LDL (Bad Cholesterol) After Laparoscopic Adjustable Gastric Band Surgery
117
SECONDARY
Level of Triglycerides (Bad Cholesterol) After Laparoscopic Adjustable Gastric Band Surgery
103
SECONDARY
Level of HbA1c (Blood Test for Diabetes) After Laparoscopic Adjustable Gastric Band Surgery
5.6

Summary

This study is to evaluate the safety and efficacy of Gastric Banding for patients with body mass index (BMI) between 30-40 kg/m2 with medical conditions related to obesity.

Eligibility Criteria

Inclusion Criteria

  • Be at least 18 and equal to or less than 60 years of age.
  • BMI of at least 30 and maximum BMI of 40 with co-morbidities
  • Willingness to comply with dietary restrictions required by the protocol
  • History of obesity for at least 5 years
  • History of at least 6 months of documented failures with traditional non-surgical weight loss methods
  • Willingness to follow protocol requirements
  • If female with childbearing potential, using an appropriate form of contraception

Exclusion Criteria

  • Age less than 18, age greater than 60
  • Pregnancy
  • History of major depressive disorder or psychosis
  • Previous bariatric surgery or previous gastric surgery
  • Presence of achalasia
  • Presence of portal hypertension, cirrhosis, and/or varices
  • Patient with inflammatory disease of the gastrointestinal tract such as Crohn's Disease
  • Patients with autoimmune connective tissue disorders
  • Patients with acute abdominal infections
  • Any condition that, in the judgment of the investigator, would place a subject at undue risk, or potentially compromise the results or interpretation of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00580502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search